The Stago Group’s commitment to sustainability takes a new step forward with the release of our latest CSR report. More comprehensive, concrete, and forward-looking, it reflects the collective efforts of our international teams and subsidiaries, and the growing integration of CSR into our daily actions and long-term vision.

Since December 2019, COVID-19 is spreading worldwide and affecting people every day. 

Main symptoms are fever and cough, and most of patients recover spontaneously.

However, about 1 in 6 patients can develop breathing difficulties and in some of them the disease progresses to a more systemic disease and multiple organ dysfunction (1). Patient’s risk stratification is key to optimize COVID-19 patients flow at hospital. Stratification is currently based on characteristics of severe pneumonia and on laboratory findings.

As part of our commitment to healthcare, Stago has been closely monitoring the development of Covid 19 worldwide, implementing several actions in the past few weeks.

The Stago webinars have successfully gathered colleagues from all around the world. If you have missed the live events or are interested in reviewing it, the 30-minute recorded version is now available online 24/7.

In April 2017, Stago officially launched its IFU (Instruction for Use) platform at www.stago.com so that customers worldwide could visit and download reagent instructions, analyser reference manuals and safety data sheets that they need for their day-to-day work.